Addressing Treatment Dilemmas in Neovascular AMD and DME

Ehsan Rahimy, MD addresses barriers like step edits with bevacizumab and biosimilars in nAMD, emphasizing the impact of insurance-guided choices on treatment outcomes and advocating for a personalized approach.

Retina expert shares his strategy for managing a patient recently diagnosed with nAMD who started on bevacizumab, discussing criteria for transitioning to more efficacious therapy.

Ehsan Rahimy, MD, discusses challenges in managing longstanding nAMD patients rotating through anti-VEGF treatments, highlighting the promise of newer therapies like aflibercept 8mg and faricimab.

An expert retina specialist discusses challenges faced by DME patients showing suboptimal response to standard anti-VEGF treatment, emphasizing the need to reduce injection burden while preventing vision loss.

Ehsan Rahimy, MD, outlines strategies for managing cases of high-risk PDR and DME, exploring new therapies and synergistic combinations with anti-VEGF and steroids for longer-lasting responses.